Siemens, Philips, J&J Attuned To Stereotaxis Public Offering, Future Sales
This article was originally published in The Gray Sheet
Executive Summary
Stereotaxis will increase sales and marketing capacity for its Stereotaxis advanced cardiology instrument control system with part of the estimated $87.9 mil. the firm expects to raise through an IPO
You may also be interested in...
Cardiology Magnet May Prove Attractive To Other Procedures – Stereotaxis
Stereotaxis'Niobe magnetic navigation system will deliver therapeutic benefits to previously unaddressed areas of interventional cardiology, the firm anticipates
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”